JP2025515237A - Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子 - Google Patents

Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子 Download PDF

Info

Publication number
JP2025515237A
JP2025515237A JP2025513209A JP2025513209A JP2025515237A JP 2025515237 A JP2025515237 A JP 2025515237A JP 2025513209 A JP2025513209 A JP 2025513209A JP 2025513209 A JP2025513209 A JP 2025513209A JP 2025515237 A JP2025515237 A JP 2025515237A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
polypeptide
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025513209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515237A5 (enExample
Inventor
フランチェスコ ボリエッロ，
アレクシス ハイラム ラモス，
ヴィンセント フラピエ，
ホンルー リー，
Original Assignee
ジェネレイト バイオメディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネレイト バイオメディシンズ， インコーポレイテッド filed Critical ジェネレイト バイオメディシンズ， インコーポレイテッド
Publication of JP2025515237A publication Critical patent/JP2025515237A/ja
Publication of JP2025515237A5 publication Critical patent/JP2025515237A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2025513209A 2022-05-06 2023-05-05 Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子 Pending JP2025515237A (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US202263364328P 2022-05-06 2022-05-06
US202263364331P 2022-05-06 2022-05-06
US63/364,331 2022-05-06
US63/364,328 2022-05-06
US202263381131P 2022-10-26 2022-10-26
US202263381132P 2022-10-26 2022-10-26
US63/381,131 2022-10-26
US63/381,132 2022-10-26
US202263424945P 2022-11-13 2022-11-13
US63/424,945 2022-11-13
US202263383695P 2022-11-14 2022-11-14
US63/383,695 2022-11-14
US202263385957P 2022-12-02 2022-12-02
US63/385,957 2022-12-02
US202363478650P 2023-01-05 2023-01-05
US63/478,650 2023-01-05
US202363480903P 2023-01-20 2023-01-20
US63/480,903 2023-01-20
US202363492206P 2023-03-24 2023-03-24
US63/492,206 2023-03-24
PCT/US2023/066714 WO2023215910A1 (en) 2022-05-06 2023-05-05 Antigen binding molecules targeting sars-cov-2

Publications (2)

Publication Number Publication Date
JP2025515237A true JP2025515237A (ja) 2025-05-13
JP2025515237A5 JP2025515237A5 (enExample) 2026-05-15

Family

ID=86732784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025513209A Pending JP2025515237A (ja) 2022-05-06 2023-05-05 Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子

Country Status (10)

Country Link
US (3) US11993644B2 (enExample)
EP (1) EP4519310A1 (enExample)
JP (1) JP2025515237A (enExample)
KR (1) KR20250054840A (enExample)
CN (1) CN121127489A (enExample)
AU (1) AU2023265164A1 (enExample)
CA (1) CA3250276A1 (enExample)
IL (1) IL316848A (enExample)
MX (1) MX2024013275A (enExample)
WO (1) WO2023215910A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CA3183373A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
IL316848A (en) 2022-05-06 2025-01-01 Generate Biomedicines Inc Antigen-binding molecules targeting SARS-CoV-2
EP4581051A1 (en) * 2022-08-31 2025-07-09 Boost Biopharma, Inc. Sars-cov-2 binding agents and uses thereof
JP2025537301A (ja) * 2022-11-13 2025-11-14 ジェネレイト バイオメディシンズ， インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子
WO2025151836A1 (en) * 2024-01-10 2025-07-17 The Trustees Of Columbia University In The City Of New York Antibodies against sarbecoviruses, their variants and uses thereof
WO2025235419A1 (en) 2024-05-06 2025-11-13 Generate Biomedicines, Inc. Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
WO2025235420A1 (en) * 2024-05-06 2025-11-13 Generate Biomedicines, Inc. Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
CN121299112B (zh) * 2024-09-12 2026-04-17 中国食品药品检定研究院 一种检测九型hpv疫苗或抗原原液体外相对效力的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004260884B2 (en) 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
US7622112B2 (en) 2003-12-05 2009-11-24 Jody Berry Anti-SARS monoclonal antibodies
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
MY177098A (en) 2013-08-09 2020-09-05 Astellas Pharma Inc Novel anti-human tslp receptor antibody
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
US20250263466A1 (en) 2020-02-03 2025-08-21 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
EP4121454A1 (en) 2020-03-19 2023-01-25 Imperial College Innovations Limited Coronavirus antibody
US11028167B1 (en) 2020-03-23 2021-06-08 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 3bgf
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
US20230348571A1 (en) 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
US11192940B2 (en) 2020-04-10 2021-12-07 Adagio Therapeutics, Inc. Compounds specific to coronavirus S protein and uses thereof
BR112022020706A2 (pt) 2020-04-14 2022-11-29 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
PH12022500020A1 (en) 2020-05-08 2024-05-06 Vir Biotechnology Inc Antibodies against sars-cov-2
CA3183373A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
WO2022015573A2 (en) * 2020-07-13 2022-01-20 President And Fellows Of Harvard College Sars-cov-2 antigen-binding proteins and uses thereof
US20230058162A1 (en) 2020-07-27 2023-02-23 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
KR20230127305A (ko) * 2020-12-29 2023-08-31 발-첨, 리미티드 파트너십 Covid-19에 대한 중화 단일클론 항체
EP4147716A1 (en) 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
IL316848A (en) 2022-05-06 2025-01-01 Generate Biomedicines Inc Antigen-binding molecules targeting SARS-CoV-2

Also Published As

Publication number Publication date
MX2024013275A (es) 2025-04-02
KR20250054840A (ko) 2025-04-23
WO2023215910A1 (en) 2023-11-09
US11993644B2 (en) 2024-05-28
CN121127489A (zh) 2025-12-12
IL316848A (en) 2025-01-01
CA3250276A1 (en) 2023-11-09
AU2023265164A1 (en) 2024-11-21
US20230357367A1 (en) 2023-11-09
EP4519310A1 (en) 2025-03-12
US20230357366A1 (en) 2023-11-09
US20240360203A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
US11993644B2 (en) Antigen binding molecules targeting SARS-CoV-2
US12216120B2 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20240043507A1 (en) Antibodies
CN112225798A (zh) 人类免疫缺陷病毒中和抗体及其使用方法
US20240336672A1 (en) Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
US12473560B2 (en) Antigen binding molecules targeting SARS-CoV-2
KR20230150184A (ko) SARS-CoV-2 스파이크 단백질에 결합하는 단일 도메인 항체
US20240101645A1 (en) Monoclonal antibodies against coronaviruses and uses thereof
JP2023534923A (ja) ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子
JP2025537301A (ja) Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子
US20230203134A1 (en) Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
TW202241497A (zh) 針對SARS-CoV-2棘蛋白之抗體雞尾酒療法
EP4687973A1 (en) Combined antibodies against sarbecoviruses and uses thereof
WO2025235419A1 (en) Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
WO2025235420A1 (en) Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
HK40041858A (en) Human immunodeficiency virus neutralizing antibodies and methods of use thereof
EA049454B1 (ru) ЧЕЛОВЕЧЕСКИЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА К КОРОНАВИРУСУ ТЯЖЕЛОГО ОСТРОГО РЕСПИРАТОРНОГО СИНДРОМА 2 (SARS-CoV-2)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260507